6
Views
5
CrossRef citations to date
0
Altmetric
Melanoma, Sarcoma and Brain Tumors

Hyperthermic Isolated Perfusion with Low-Dose TNFα and Doxorubicin in Patients with Locally Advanced Soft Tissue Limb Sarcomas

, , , , , , & show all
Pages 58-61 | Published online: 27 Oct 2016

References

  • Rossi CR, Mocellin S, Pilati P, Foletto M, Nitti D, Lise M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends. J Immunother 2003;26:291–300.
  • Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996;14:2653–65.
  • Vrouenraets BC, Kroon BB, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999;6:405–12.
  • Di Filippo F, Rossi CR, Vaglini M, et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. J Immunother 1999;22:407–14.
  • Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas. Cancer 1994;73:2140–6.
  • Casara D, Rubello D, Pilati P. A simplified procedure for continuous intraoperative external monitoring of systemic leakage during isolated limb perfusion cancer therapy. Eur J Nuclear Med 2001;28:1174.
  • Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905–10.
  • Hill S, Fawcett WJ, Sheldon J, Soni N, Williams T, Thomas JM. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995–7.
  • Watanabe N, Niitsu Y, Umeno H, et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988;48:650–3.
  • van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intra-tumoural concentrations of doxorubicin in TNF- alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000;82:973–80.
  • Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756–64; discussion 764–5.
  • Bonvalot S, Lejeune F, Laplanche A, Le Péchoux C et al. Limb salvage by isolated limb perfusion in patients with locally advanced soft tissue limb sarcomas : randomized phase II study comparing four doses of TNF. Proceedings of 3rd Expert Meeting Beromun, 2003 October 3–4; Madrid.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.